TurkeyTuberculosis profile
Population  2014 78 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.47 (0.4–0.55) 0.61 (0.52–0.7)
Mortality (HIV+TB only) <0.01 (<0.01–0.012) 0.01 (0.01–0.02)
Prevalence  (includes HIV+TB) 17 (8–30) 22 (10–39)
Incidence  (includes HIV+TB) 14 (12–16) 18 (16–21)
Incidence (HIV+TB only) 0.045 (0.035–0.057) 0.06 (0.05–0.07)
         
Case detection, all forms (%) 93 (82–110)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (2.1–3) 18 (15–21)
MDR-TB cases among notified pulmonary
TB cases
190 (160–230) 170 (140–200)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 5 799   568
Pulmonary, clinically diagnosed 1 897   119
Extrapulmonary 4 557   168
       
Total new and relapse 13 108    
Previously treated, excluding relapses 270    
Total cases notified 13 378    
Among 13 108 new and relapse cases:
550 (4%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 4 866 (84%) 630 (56%) 5 496
Laboratory-confirmed RR-/MDR-TB cases     349
Patients started on MDR-TB treatment ***     257
TB/HIV 2014 Number (%)
TB patients with known HIV status 9 344 (70)
HIV-positive TB patients 45 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 13 (29)
HIV-positive TB patients on antiretroviral therapy (ART) 28 (62)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (86) 13 170
Previously treated cases, excluding relapse, registered in 2013 (38) 239
HIV-positive TB cases, all types, registered in 2013 (53) 32
RR-/MDR-TB cases started on second-line treatment in 2012 (66) 291
XDR-TB cases started on second-line treatment in 2012 (67) 6
Laboratories 2014  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 9.9
Drug susceptibility testing (per 5 million population) 4.9
Sites performing Xpert MTB/RIF 24
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-26 Data: www.who.int/tb/data